In a cross-sectional and longitudinal study, Qiu et al. (2013) reported that “angiotensin converting enzyme inhibitors, especially peripherally acting ones, are associated with a reduced risk of AD in the absence of apoE4, but had no such effect in those carrying the apoE4 allele.” This paper is noticeable because it is an example of the various papers showing, also in AD mouse models, that peripheral interventions may result in CNS benefits. The gene discussed is ACE; the disease is Alzheimer disease.